Protocol Ledger

NCT03259334 · Phase III · TERMINATED

Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis

Interventional Phase III clinical trial protocol NCT03259334 sponsored by Takeda in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-02-09 Enrollment: 380 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03259334
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)380 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03259334
Protocol FieldVerified Registry Value
NCT IdentifierNCT03259334
Consolidated Lead SponsorTakeda
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment380 participants (ACTUAL)
Registered Start Date2018-02-09
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI